FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1575991619> ?p ?o ?g. }

• W1575991619 endingPage "655" @default.
• W1575991619 startingPage "647" @default.
• W1575991619 abstract "A phase II trial was designed to explore the potential feasibility and efficacy of a reinduction therapy consisting of fludarabine, cytarabine, idarubicin and granulocyte colony stimulating factor (G-CSF) for acute myelogenous leukaemia (AML) patients with poor prognosis. Twenty-three patients aged 1.2–17.5 years with refractory (n = 3), relapsed (n = 19) or secondary (n = 1) AML were treated with the IDA-FLAG regimen, a combination therapy of idarubicin (days 2–4, 12 mg/m2/d), fludarabine (days 1–4, 30 mg/m2/d), cytarabine (days 1–4, 2000 mg/m2/d) and G-CSF (day 0 up to ANC > 1 × 109/l, 400 μg/m2/d). They received a total of 37 courses of IDA-FLAG and/or FLAG (IDA-FLAG without idarubicin). 17/23 patients achieved a complete remission (CR) with a median duration of 13.5 months (1–39 months), one patient showed a partial remission, and five were nonresponders while in CR, 11 patients underwent bone marrow or PBSC (peripheral blood stem cells) transplantation. Overall, nine patients remain in continuous complete remission with a median duration of 17.5 months (9.5–39 months). The toxicity of the IDA-FLAG courses was more severe than for the FLAG courses with marked neutropenia and thrombocytopenia (for IDA-FLAG: median 22.5 and 25 d respectively; for FLAG: median 10.5 and 14 d respectively). Pulmonary infections were the main nonhaematological toxicity. One patient died in CR from invasive aspergillosis. The IDA-FLAG regimen produced a CR of >12 months in more than half of the patients and can be recommended as a therapeutic option prior to allogeneic or autologous bone marrow transplantation." @default.
• W1575991619 created "2016-06-24" @default.
• W1575991619 creator A5015761988 @default.
• W1575991619 creator A5027639619 @default.
• W1575991619 creator A5029830172 @default.
• W1575991619 creator A5074936670 @default.
• W1575991619 creator A5084711206 @default.
• W1575991619 date "1998-08-01" @default.
• W1575991619 modified "2023-10-04" @default.
• W1575991619 title "IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial" @default.
• W1575991619 cites W1143126211 @default.
• W1575991619 cites W1481564836 @default.
• W1575991619 cites W1709114039 @default.
• W1575991619 cites W1819781110 @default.
• W1575991619 cites W1857665725 @default.
• W1575991619 cites W1860795225 @default.
• W1575991619 cites W1870350942 @default.
• W1575991619 cites W1891825979 @default.
• W1575991619 cites W1907898477 @default.
• W1575991619 cites W1925684361 @default.
• W1575991619 cites W1969474912 @default.
• W1575991619 cites W2001584634 @default.
• W1575991619 cites W2013492592 @default.
• W1575991619 cites W2016395017 @default.
• W1575991619 cites W2029007438 @default.
• W1575991619 cites W2048312112 @default.
• W1575991619 cites W2053932874 @default.
• W1575991619 cites W2054714648 @default.
• W1575991619 cites W2066270160 @default.
• W1575991619 cites W2070044750 @default.
• W1575991619 cites W2096748176 @default.
• W1575991619 cites W2145635831 @default.
• W1575991619 cites W2157633619 @default.
• W1575991619 cites W2165507228 @default.
• W1575991619 cites W2327592010 @default.
• W1575991619 cites W2400592224 @default.
• W1575991619 cites W2409551310 @default.
• W1575991619 doi "https://doi.org/10.1046/j.1365-2141.1998.00836.x" @default.
• W1575991619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9722289" @default.
• W1575991619 hasPublicationYear "1998" @default.
• W1575991619 type Work @default.
• W1575991619 sameAs 1575991619 @default.
• W1575991619 citedByCount "82" @default.
• W1575991619 countsByYear W15759916192012 @default.
• W1575991619 countsByYear W15759916192013 @default.
• W1575991619 countsByYear W15759916192014 @default.
• W1575991619 countsByYear W15759916192015 @default.
• W1575991619 countsByYear W15759916192016 @default.
• W1575991619 countsByYear W15759916192017 @default.
• W1575991619 countsByYear W15759916192018 @default.
• W1575991619 countsByYear W15759916192019 @default.
• W1575991619 countsByYear W15759916192020 @default.
• W1575991619 countsByYear W15759916192021 @default.
• W1575991619 countsByYear W15759916192022 @default.
• W1575991619 countsByYear W15759916192023 @default.
• W1575991619 crossrefType "journal-article" @default.
• W1575991619 hasAuthorship W1575991619A5015761988 @default.
• W1575991619 hasAuthorship W1575991619A5027639619 @default.
• W1575991619 hasAuthorship W1575991619A5029830172 @default.
• W1575991619 hasAuthorship W1575991619A5074936670 @default.
• W1575991619 hasAuthorship W1575991619A5084711206 @default.
• W1575991619 hasBestOaLocation W15759916191 @default.
• W1575991619 hasConcept C126322002 @default.
• W1575991619 hasConcept C136119220 @default.
• W1575991619 hasConcept C141071460 @default.
• W1575991619 hasConcept C202444582 @default.
• W1575991619 hasConcept C2776694085 @default.
• W1575991619 hasConcept C2776730729 @default.
• W1575991619 hasConcept C2776755627 @default.
• W1575991619 hasConcept C2777063308 @default.
• W1575991619 hasConcept C2777767877 @default.
• W1575991619 hasConcept C2778041864 @default.
• W1575991619 hasConcept C2779117419 @default.
• W1575991619 hasConcept C2779263901 @default.
• W1575991619 hasConcept C2781413609 @default.
• W1575991619 hasConcept C2911091166 @default.
• W1575991619 hasConcept C33923547 @default.
• W1575991619 hasConcept C71924100 @default.
• W1575991619 hasConcept C90924648 @default.
• W1575991619 hasConceptScore W1575991619C126322002 @default.
• W1575991619 hasConceptScore W1575991619C136119220 @default.
• W1575991619 hasConceptScore W1575991619C141071460 @default.
• W1575991619 hasConceptScore W1575991619C202444582 @default.
• W1575991619 hasConceptScore W1575991619C2776694085 @default.
• W1575991619 hasConceptScore W1575991619C2776730729 @default.
• W1575991619 hasConceptScore W1575991619C2776755627 @default.
• W1575991619 hasConceptScore W1575991619C2777063308 @default.
• W1575991619 hasConceptScore W1575991619C2777767877 @default.
• W1575991619 hasConceptScore W1575991619C2778041864 @default.
• W1575991619 hasConceptScore W1575991619C2779117419 @default.
• W1575991619 hasConceptScore W1575991619C2779263901 @default.
• W1575991619 hasConceptScore W1575991619C2781413609 @default.
• W1575991619 hasConceptScore W1575991619C2911091166 @default.
• W1575991619 hasConceptScore W1575991619C33923547 @default.
• W1575991619 hasConceptScore W1575991619C71924100 @default.
• W1575991619 hasConceptScore W1575991619C90924648 @default.
• W1575991619 hasIssue "3" @default.
• W1575991619 hasLocation W15759916191 @default.

• next